InfuSystem Holdings, Inc. (INFU) Income Statement Analysis

See more : E & M Computing Ltd. (EMCO.TA) Income Statement Analysis – Financial Results

Complete financial analysis of InfuSystem Holdings, Inc. (INFU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InfuSystem Holdings, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

InfuSystem Holdings, Inc. (INFU)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.infusystem.com

About InfuSystem Holdings, Inc.

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
Revenue	125.79M	109.91M	102.38M	97.39M	81.12M	67.14M	71.08M	70.50M	72.13M	66.49M	62.28M	58.83M	54.64M	47.23M	38.96M	35.42M	6.58M	0.00	0.00
Cost of Revenue	62.68M	47.34M	42.19M	38.63M	34.23M	28.12M	27.72M	25.76M	20.94M	19.13M	18.60M	15.92M	19.28M	13.68M	10.33M	9.19M	1.62M	0.00	0.00
Gross Profit	63.11M	62.57M	60.20M	58.76M	46.88M	39.02M	43.36M	44.74M	51.18M	47.35M	43.68M	42.91M	35.36M	33.55M	28.64M	26.22M	4.96M	0.00	0.00
Gross Profit Ratio	50.17%	56.93%	58.80%	60.33%	57.80%	58.12%	61.01%	63.46%	70.97%	71.22%	70.13%	72.94%	64.71%	71.03%	73.50%	74.05%	75.39%	0.00%	0.00%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	45.38M	46.08M	42.26M	35.20M	29.02M	24.85M	25.20M	24.63M	23.78M	19.99M	18.97M	23.06M	17.99M	20.62M	12.22M	11.77M	4.89M	919.22B	0.00
Selling & Marketing	12.65M	12.26M	10.78M	9.66M	9.93M	9.11M	9.78M	9.66M	10.42M	9.75M	9.66M	9.86M	9.37M	7.09M	5.26M	4.66M	649.00K	-919.20B	0.00
SG&A	58.03M	58.34M	53.04M	44.86M	38.96M	33.95M	34.98M	34.29M	34.20M	29.73M	28.63M	32.93M	27.36M	27.71M	17.48M	16.42M	6.12M	20.82M	24.48K
Other Expenses	990.00K	2.58M	4.34M	5.08M	4.40M	-37.00K	-113.00K	6.00K	13.00K	13.00K	301.00K	-141.00K	6.76M	6.77M	5.83M	5.01M	6.46M	20.82M	0.00
Operating Expenses	59.02M	60.92M	57.38M	49.93M	43.36M	38.60M	46.18M	43.77M	42.32M	38.02M	37.78M	40.91M	34.12M	34.48M	23.31M	21.44M	6.46M	20.82M	24.48K
Cost & Expenses	121.70M	108.26M	99.56M	88.56M	77.59M	66.72M	73.90M	69.52M	63.26M	57.16M	56.38M	56.83M	53.40M	48.17M	33.64M	30.63M	8.08M	20.82M	24.48K
Interest Income	0.00	1.40M	1.38M	1.26M	1.90M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.00K	36.00K	3.88M	3.20M	0.00
Interest Expense	2.17M	1.40M	1.38M	1.26M	1.90M	1.42M	1.33M	1.34M	1.71M	3.13M	3.50M	3.34M	2.19M	3.35M	3.50M	3.77M	774.00K	1.30K	300.00
Depreciation & Amortization	12.51M	13.36M	14.63M	14.03M	12.34M	11.31M	12.52M	10.74M	8.24M	6.14M	8.03M	8.40M	9.05M	8.60M	6.44M	6.40M	862.00K	6.66M	0.00
EBITDA	16.50M	15.09M	17.15M	22.82M	15.77M	11.69M	8.60M	11.72M	13.94M	15.49M	14.23M	9.45M	-57.34M	7.75M	11.69M	20.40M	-635.00K	-6.82M	-24.48K
EBITDA Ratio	13.11%	13.55%	16.86%	23.44%	19.44%	17.41%	13.49%	16.63%	23.74%	23.29%	22.85%	17.44%	18.82%	16.21%	30.22%	31.70%	40.40%	0.00%	0.00%
Operating Income	4.09M	1.65M	2.82M	8.83M	3.53M	415.00K	-3.81M	974.00K	8.86M	9.33M	5.90M	2.00M	-66.36M	-938.00K	5.33M	4.79M	-1.50M	-20.82M	-24.48K
Operating Income Ratio	3.25%	1.50%	2.75%	9.06%	4.35%	0.62%	-5.36%	1.38%	12.29%	14.03%	9.47%	3.40%	-121.45%	-1.99%	13.67%	13.51%	-22.74%	0.00%	0.00%
Total Other Income/Expenses	-2.24M	-1.52M	-1.56M	-1.28M	-2.00M	-1.46M	-1.45M	-1.34M	-3.29M	-3.12M	-3.20M	-4.15M	-2.22M	-2.29M	-3.58M	6.08M	-189.00K	-6,821.45B	0.00
Income Before Tax	1.85M	130.00K	1.26M	7.54M	1.52M	-1.04M	-5.26M	-364.00K	5.57M	6.21M	2.70M	-2.15M	-68.58M	-3.22M	1.75M	10.87M	-1.69M	-6.82M	0.00
Income Before Tax Ratio	1.47%	0.12%	1.23%	7.75%	1.88%	-1.55%	-7.40%	-0.52%	7.73%	9.34%	4.34%	-3.66%	-125.51%	-6.82%	4.49%	30.68%	-25.62%	0.00%	0.00%
Income Tax Expense	979.00K	112.00K	-163.00K	-9.79M	163.00K	53.00K	15.45M	-142.00K	1.83M	2.85M	1.03M	-663.00K	-23.13M	-1.37M	977.00K	907.00K	1.11M	1.04M	24.78K
Net Income	872.00K	18.00K	1.42M	17.33M	1.36M	-1.10M	-20.71M	-222.00K	3.74M	3.36M	1.67M	-1.49M	-45.44M	-1.85M	774.00K	9.96M	-2.80M	-7.86M	-24.78K
Net Income Ratio	0.69%	0.02%	1.39%	17.80%	1.68%	-1.63%	-29.13%	-0.31%	5.19%	5.05%	2.68%	-2.53%	-83.17%	-3.92%	1.99%	28.12%	-42.48%	0.00%	0.00%
EPS	0.04	0.00	0.07	0.86	0.07	-0.05	-0.91	-0.01	0.17	0.15	0.08	-0.07	-2.16	-0.09	0.04	0.56	-0.15	-0.58	-0.01
EPS Diluted	0.04	0.00	0.06	0.80	0.07	-0.05	-0.91	-0.01	0.16	0.15	0.08	-0.07	-2.16	-0.09	0.04	0.53	-0.15	-0.58	-0.01
Weighted Avg Shares Out	21.02M	20.65M	20.52M	20.11M	19.73M	21.42M	22.74M	22.20M	22.41M	22.15M	21.87M	21.27M	21.07M	19.72M	18.61M	17.94M	18.30M	13.66M	3.25M
Weighted Avg Shares Out (Dil)	21.65M	21.55M	22.05M	21.72M	20.84M	21.42M	22.74M	22.62M	22.84M	22.55M	22.07M	21.43M	21.07M	19.72M	18.93M	18.67M	18.30M	13.66M	3.25M

InfuSystem to Present at Sidoti Small-Cap Virtual Conference on December 6, 2023

November 28, 2023businesswire.com

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Present at Sidoti Small-Cap Virtual Conference on December 6, 2023.

InfuSystem to Participate at 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023

November 9, 2023businesswire.com

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate at 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023.

InfuSystem Holdings, Inc. (INFU) Q3 2023 Earnings Call Transcript

November 7, 2023seekingalpha.com

InfuSystem Holdings, Inc. (INFU) Q3 2023 Earnings Call Transcript

InfuSystem Reports Third Quarter 2023 Financial Results

November 7, 2023businesswire.com

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem Reports Third Quarter 2023 Financial Results.

InfuSystem to Report Third Quarter 2023 Financial Results on November 7, 2023

October 31, 2023businesswire.com

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Report Third Quarter 2023 Financial Results on November 7, 2023.

Dignitana announces a sales and marketing partnership with InfuSystem to provide scalp cooling systems in the United States

October 4, 2023prnewswire.com

LUND, Sweden , Oct. 4, 2023 /PRNewswire/ -- Scalp cooling innovator Dignitana AB announces today a sales and marketing partnership with InfuSystem Holdings, Inc., a leading health care service provider facilitating outpatient care for durable medical equipment manufacturers and health...

InfuSystem to Participate in Lake Street's 7th Annual Best Ideas Growth (BIG7) Conference September 14, 2023

September 5, 2023businesswire.com

ROCHESTER HILLS, Mich.--(BUSINESS WIRE)--InfuSystem to Participate in Lake Street's 7th Annual Best Ideas Growth (BIG7) Conference September 14, 2023.

InfuSystem Holdings, Inc. (INFU) Q2 2023 Earnings Call Transcript

August 4, 2023seekingalpha.com

InfuSystem Holdings, Inc. (NYSE:INFU ) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Joe Dorame - Managing Partner Richard DiIorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and...